Worth reading
47Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Neutral
Direction inferred from the company’s description.Scale
16
Sites in JapanWording
Conditional
How definitive the wording is.Announced details
DFP-17729 (tumor microenvironment-modifying agent)
Applicable field (uses covered by this announcement)
Third-line and later treatment of pancreatic cancer
What the company reported numerically
Quantitative Effects
A trial design that efficiently evaluates survival. The number of patients in the Phase 3 portion will increase or decrease based on the degree of superiority confirmed in the Phase 2 portion.
Usage history
The first patient was enrolled in August 2025. The Phase 2 portion is currently being conducted at 16 sites in Japan.
Location (as indicated in this announcement)
16 sites in Japan
In this announcement the company addresses none of Contract Value / Offering price / Impact on Business Performance.
| Item | Details |
|---|---|
| Names of Products / Services Covered | DFP-17729 (tumor microenvironment-modifying agent) |
| Applicable area | Third-line and later treatment of pancreatic cancer |
| Location scale | 16 sites in Japan |
| Quantitative Effects | A trial design that efficiently evaluates survival. The number of patients in the Phase 3 portion will increase or decrease based on the degree of superiority confirmed in the Phase 2 portion. |
| Usage history | The first patient was enrolled in August 2025. The Phase 2 portion is currently being conducted at 16 sites in Japan. |
Items this document does not state (13)
CounterpartyCounterparty overviewRelationship with the CompanyContract ValueOffering priceContract DateLaunch dateAward/certification nameAwarding / certifying bodyRegistration number and expiry dateLocationImpact on Business PerformanceSource
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Patient enrollment is progressing smoothly with the cooperation of each site.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.